Literature DB >> 10877225

Erythromycin-induced primary biliary cirrhosis.

D A Lazarczyk1, M C Duffy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877225     DOI: 10.1023/a:1005589616735

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  16 in total

1.  Chronic chlorpromazine jaundice: with particular reference to its relationship to primary biliary cirrhosis.

Authors:  A E READ; C V HARRISON; S SHERLOVK
Journal:  Am J Med       Date:  1961-08       Impact factor: 4.965

2.  Natural history of early primary biliary cirrhosis.

Authors:  J V Metcalf; H C Mitchison; J M Palmer; D E Jones; M F Bassendine; O F James
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

Review 3.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

4.  Biliary cirrhosis induced by chlorpromazine.

Authors:  C O Walker; B Combes
Journal:  Gastroenterology       Date:  1966-11       Impact factor: 22.682

Review 5.  Flucloxacillin-associated hepatic injury.

Authors:  G H Koek; B H Stricker; A P Blok; S W Schalm; V J Desmet
Journal:  Liver       Date:  1994-10

6.  High incidence of poor sulfoxidation in patients with primary biliary cirrhosis.

Authors:  A B Olomu; C R Vickers; R H Waring; D Clements; C Babbs; T W Warnes; E Elias
Journal:  N Engl J Med       Date:  1988-04-28       Impact factor: 91.245

7.  NIH conference: Primary biliary cirrhosis: a model autoimmune disease.

Authors:  S P James; J H Hoofnagle; W Strober; E A Jones
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

Review 8.  Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection.

Authors:  E D'Amico; M Paroli; V Fratelli; C Palazzi; V Barnaba; F Callea; G Consoli
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

9.  Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis.

Authors:  D Moradpour; J Altorfer; R Flury; P Greminger; C Meyenberger; R Jost; M Schmid
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

Review 10.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-04       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.